Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-06-06

AUTHORS

Jakub Wroński, Piotr Fiedor, Piotr Głuszko

ABSTRACT

Background Although TNF inhibitors are well established in ankylosing spondylitis treatment, the majority of studies on TNF inhibitors safety have been performed in rheumatoid arthritis patients. Meanwhile, it seems that TNF inhibitors in ankylosing spondylitis may present a better safety profile than we thought. Objective The aim of our study was to retrospectively investigate the occurrence of adverse events in ankylosing spondylitis patients treated with TNF inhibitors. Setting A single referral center in Poland. Methods Detailed medical history of ankylosing spondylitis patients was obtained during the interview with the patient and by reviewing electronic medical records. Patients treated with TNF inhibitors and patients without TNF inhibitors treatment were compared. Main outcome measure The incidence of adverse events during the 3 months period before the interview. Results A total of 150 patients, 103 in the treatment group and 47 in the control group, were included in the study. There were no differences in the incidence of adverse events, serious adverse events, infections and opportunistic infections between both groups. However, in the treatment group, noninfectious adverse events were significantly less frequent than in control group (RR 0.39, 95% CI 0.23-0.66), with abdominal pain as the most common noninfectious adverse event (RR 0.20, 95% CI 0.07-0.63). The differences in incidence rates of specific infections were not significant, except acute infectious diarrhea which also was less frequent in patients treated with TNF inhibitors (RR 0.17, 95% CI 0.03-0.85). The female gender was significantly associated with any adverse event occurrence (OR 2.36, 95% CI 1.15-4.83). Conclusion TNF inhibitors show a good safety profile in ankylosing spondylitis patients. More... »

PAGES

864-871

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11096-019-00859-7

DOI

http://dx.doi.org/10.1007/s11096-019-00859-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1116839286

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31172410


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abdominal Pain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Poland", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sex Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spondylitis, Ankylosing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor Inhibitors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland", 
          "id": "http://www.grid.ac/institutes/grid.13339.3b", 
          "name": [
            "Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Sparta\u0144ska 1, 02-637 Warsaw, Poland", 
            "Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wro\u0144ski", 
        "givenName": "Jakub", 
        "id": "sg:person.0733571600.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733571600.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland", 
          "id": "http://www.grid.ac/institutes/grid.13339.3b", 
          "name": [
            "Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fiedor", 
        "givenName": "Piotr", 
        "id": "sg:person.01152477672.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152477672.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Sparta\u0144ska 1, 02-637 Warsaw, Poland", 
          "id": "http://www.grid.ac/institutes/grid.460480.e", 
          "name": [
            "Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Sparta\u0144ska 1, 02-637 Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u0142uszko", 
        "givenName": "Piotr", 
        "id": "sg:person.01142466703.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142466703.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10067-013-2387-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008318128", 
          "https://doi.org/10.1007/s10067-013-2387-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12016-017-8623-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090743106", 
          "https://doi.org/10.1007/s12016-017-8623-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep32768", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007149680", 
          "https://doi.org/10.1038/srep32768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00296-013-2772-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024479511", 
          "https://doi.org/10.1007/s00296-013-2772-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-06-06", 
    "datePublishedReg": "2019-06-06", 
    "description": "Background Although TNF inhibitors are well established in ankylosing spondylitis treatment, the majority of studies on TNF inhibitors safety have been performed in rheumatoid arthritis patients. Meanwhile, it seems that TNF inhibitors in ankylosing spondylitis may present a better safety profile than we thought. Objective The aim of our study was to retrospectively investigate the occurrence of adverse events in ankylosing spondylitis patients treated with TNF inhibitors. Setting A single referral center in Poland. Methods Detailed medical history of ankylosing spondylitis patients was obtained during the interview with the patient and by reviewing electronic medical records. Patients treated with TNF inhibitors and patients without TNF inhibitors treatment were compared. Main outcome measure The incidence of adverse events during the 3\u00a0months period before the interview. Results A total of 150 patients, 103 in the treatment group and 47 in the control group, were included in the study. There were no differences in the incidence of adverse events, serious adverse events, infections and opportunistic infections between both groups. However, in the treatment group, noninfectious adverse events were significantly less frequent than in control group (RR 0.39, 95% CI 0.23-0.66), with abdominal pain as the most common noninfectious adverse event (RR 0.20, 95% CI 0.07-0.63). The differences in incidence rates of specific infections were not significant, except acute infectious diarrhea which also was less frequent in patients treated with TNF inhibitors (RR 0.17, 95% CI 0.03-0.85). The female gender was significantly associated with any adverse event occurrence (OR 2.36, 95% CI 1.15-4.83). Conclusion TNF inhibitors show a good safety profile in ankylosing spondylitis patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11096-019-00859-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044817", 
        "issn": [
          "2210-7703", 
          "2210-7711"
        ], 
        "name": "International Journal of Clinical Pharmacy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "41"
      }
    ], 
    "keywords": [
      "noninfectious adverse events", 
      "TNF inhibitors", 
      "adverse events", 
      "good safety profile", 
      "spondylitis patients", 
      "safety profile", 
      "treatment groups", 
      "control group", 
      "TNF inhibitor treatment", 
      "single referral center", 
      "serious adverse events", 
      "acute infectious diarrhea", 
      "rheumatoid arthritis patients", 
      "detailed medical history", 
      "cross-sectional study", 
      "adverse event occurrence", 
      "electronic medical records", 
      "abdominal pain", 
      "referral center", 
      "arthritis patients", 
      "opportunistic infections", 
      "infectious diarrhea", 
      "medical history", 
      "medical records", 
      "incidence rate", 
      "spondylitis treatment", 
      "specific infections", 
      "female gender", 
      "MAIN OUTCOME", 
      "patients", 
      "inhibitor treatment", 
      "majority of studies", 
      "infection", 
      "month period", 
      "spondylitis", 
      "inhibitors", 
      "incidence", 
      "treatment", 
      "group", 
      "pain", 
      "diarrhea", 
      "study", 
      "events", 
      "outcomes", 
      "differences", 
      "total", 
      "occurrence", 
      "interviews", 
      "safety", 
      "gender", 
      "aim", 
      "majority", 
      "profile", 
      "period", 
      "records", 
      "history", 
      "center", 
      "event occurrence", 
      "background", 
      "rate", 
      "results", 
      "Poland", 
      "TNF inhibitors safety", 
      "inhibitors safety", 
      "Methods Detailed medical history", 
      "common noninfectious adverse event", 
      "Conclusion TNF inhibitors"
    ], 
    "name": "Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study", 
    "pagination": "864-871", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1116839286"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11096-019-00859-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31172410"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11096-019-00859-7", 
      "https://app.dimensions.ai/details/publication/pub.1116839286"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:55", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_827.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11096-019-00859-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-019-00859-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-019-00859-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-019-00859-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-019-00859-7'


 

This table displays all metadata directly associated to this object as RDF triples.

223 TRIPLES      22 PREDICATES      112 URIs      100 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11096-019-00859-7 schema:about N179a843f80dc42f080220d1a7e876444
2 N23bb671033e64740ace0104f9da1c6a4
3 N4040ecbcfe5e430591be366593032d8a
4 N4da63fd8e95840d2989ca838d292c4b7
5 N5485c077257f4251b2c2a4d6091de557
6 N638b8c0b72374ed3bdfef9d319a0eb08
7 N655c621d13374877b9445beefb109f9d
8 N6fc8b9295aea4f53a15ac6fa5200f8a7
9 N7e30acdbc6354c65a2245fb60031fc43
10 N7f24404662844456ba56624d602e1079
11 N85246da9a2f346a5b2b778e40dcd7ad3
12 N8a78a8d57c864ec18c6a7914620fa86e
13 Nc149f8fca60048918c81117121542ca6
14 Nc6ad9144fe814cf484b96fae7c2ca506
15 Ncedccc264be047169e943a6c77ac89bb
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N77a96d50af5d4116b29c1d14fec7d5bd
19 schema:citation sg:pub.10.1007/s00296-013-2772-6
20 sg:pub.10.1007/s10067-013-2387-z
21 sg:pub.10.1007/s12016-017-8623-6
22 sg:pub.10.1038/srep32768
23 schema:datePublished 2019-06-06
24 schema:datePublishedReg 2019-06-06
25 schema:description Background Although TNF inhibitors are well established in ankylosing spondylitis treatment, the majority of studies on TNF inhibitors safety have been performed in rheumatoid arthritis patients. Meanwhile, it seems that TNF inhibitors in ankylosing spondylitis may present a better safety profile than we thought. Objective The aim of our study was to retrospectively investigate the occurrence of adverse events in ankylosing spondylitis patients treated with TNF inhibitors. Setting A single referral center in Poland. Methods Detailed medical history of ankylosing spondylitis patients was obtained during the interview with the patient and by reviewing electronic medical records. Patients treated with TNF inhibitors and patients without TNF inhibitors treatment were compared. Main outcome measure The incidence of adverse events during the 3 months period before the interview. Results A total of 150 patients, 103 in the treatment group and 47 in the control group, were included in the study. There were no differences in the incidence of adverse events, serious adverse events, infections and opportunistic infections between both groups. However, in the treatment group, noninfectious adverse events were significantly less frequent than in control group (RR 0.39, 95% CI 0.23-0.66), with abdominal pain as the most common noninfectious adverse event (RR 0.20, 95% CI 0.07-0.63). The differences in incidence rates of specific infections were not significant, except acute infectious diarrhea which also was less frequent in patients treated with TNF inhibitors (RR 0.17, 95% CI 0.03-0.85). The female gender was significantly associated with any adverse event occurrence (OR 2.36, 95% CI 1.15-4.83). Conclusion TNF inhibitors show a good safety profile in ankylosing spondylitis patients.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N271810e6cabe421cacfa6e2d130ecb26
30 N6e728e791a6a410c9b062664f40b5a86
31 sg:journal.1044817
32 schema:keywords Conclusion TNF inhibitors
33 MAIN OUTCOME
34 Methods Detailed medical history
35 Poland
36 TNF inhibitor treatment
37 TNF inhibitors
38 TNF inhibitors safety
39 abdominal pain
40 acute infectious diarrhea
41 adverse event occurrence
42 adverse events
43 aim
44 arthritis patients
45 background
46 center
47 common noninfectious adverse event
48 control group
49 cross-sectional study
50 detailed medical history
51 diarrhea
52 differences
53 electronic medical records
54 event occurrence
55 events
56 female gender
57 gender
58 good safety profile
59 group
60 history
61 incidence
62 incidence rate
63 infection
64 infectious diarrhea
65 inhibitor treatment
66 inhibitors
67 inhibitors safety
68 interviews
69 majority
70 majority of studies
71 medical history
72 medical records
73 month period
74 noninfectious adverse events
75 occurrence
76 opportunistic infections
77 outcomes
78 pain
79 patients
80 period
81 profile
82 rate
83 records
84 referral center
85 results
86 rheumatoid arthritis patients
87 safety
88 safety profile
89 serious adverse events
90 single referral center
91 specific infections
92 spondylitis
93 spondylitis patients
94 spondylitis treatment
95 study
96 total
97 treatment
98 treatment groups
99 schema:name Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study
100 schema:pagination 864-871
101 schema:productId N06537c11dfae40ccbd37ca40a9cf2c1c
102 N366791da76d64f55965aeecb33587117
103 N95ed8afaba274598b18a3c936c68f293
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1116839286
105 https://doi.org/10.1007/s11096-019-00859-7
106 schema:sdDatePublished 2022-01-01T18:55
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N7066ccb0c17c42859ee8370684c4462b
109 schema:url https://doi.org/10.1007/s11096-019-00859-7
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N06537c11dfae40ccbd37ca40a9cf2c1c schema:name doi
114 schema:value 10.1007/s11096-019-00859-7
115 rdf:type schema:PropertyValue
116 N179a843f80dc42f080220d1a7e876444 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Incidence
118 rdf:type schema:DefinedTerm
119 N23bb671033e64740ace0104f9da1c6a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Abdominal Pain
121 rdf:type schema:DefinedTerm
122 N271810e6cabe421cacfa6e2d130ecb26 schema:volumeNumber 41
123 rdf:type schema:PublicationVolume
124 N366791da76d64f55965aeecb33587117 schema:name pubmed_id
125 schema:value 31172410
126 rdf:type schema:PropertyValue
127 N4040ecbcfe5e430591be366593032d8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Cross-Sectional Studies
129 rdf:type schema:DefinedTerm
130 N4da63fd8e95840d2989ca838d292c4b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 N5485c077257f4251b2c2a4d6091de557 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Tumor Necrosis Factor Inhibitors
135 rdf:type schema:DefinedTerm
136 N638b8c0b72374ed3bdfef9d319a0eb08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Case-Control Studies
138 rdf:type schema:DefinedTerm
139 N655c621d13374877b9445beefb109f9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 N6e728e791a6a410c9b062664f40b5a86 schema:issueNumber 4
143 rdf:type schema:PublicationIssue
144 N6fc8b9295aea4f53a15ac6fa5200f8a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Spondylitis, Ankylosing
146 rdf:type schema:DefinedTerm
147 N7066ccb0c17c42859ee8370684c4462b schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N77a96d50af5d4116b29c1d14fec7d5bd rdf:first sg:person.0733571600.90
150 rdf:rest Na4024f0a5fcf45678ce9b9c964470e8e
151 N7e30acdbc6354c65a2245fb60031fc43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Infections
153 rdf:type schema:DefinedTerm
154 N7f24404662844456ba56624d602e1079 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Female
156 rdf:type schema:DefinedTerm
157 N85246da9a2f346a5b2b778e40dcd7ad3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Poland
159 rdf:type schema:DefinedTerm
160 N8a78a8d57c864ec18c6a7914620fa86e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Middle Aged
162 rdf:type schema:DefinedTerm
163 N95ed8afaba274598b18a3c936c68f293 schema:name dimensions_id
164 schema:value pub.1116839286
165 rdf:type schema:PropertyValue
166 Na4024f0a5fcf45678ce9b9c964470e8e rdf:first sg:person.01152477672.41
167 rdf:rest Nbbb9a0e52362456faeed71595b464108
168 Nbbb9a0e52362456faeed71595b464108 rdf:first sg:person.01142466703.40
169 rdf:rest rdf:nil
170 Nc149f8fca60048918c81117121542ca6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Adult
172 rdf:type schema:DefinedTerm
173 Nc6ad9144fe814cf484b96fae7c2ca506 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Retrospective Studies
175 rdf:type schema:DefinedTerm
176 Ncedccc264be047169e943a6c77ac89bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Sex Factors
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1044817 schema:issn 2210-7703
186 2210-7711
187 schema:name International Journal of Clinical Pharmacy
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01142466703.40 schema:affiliation grid-institutes:grid.460480.e
191 schema:familyName Głuszko
192 schema:givenName Piotr
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142466703.40
194 rdf:type schema:Person
195 sg:person.01152477672.41 schema:affiliation grid-institutes:grid.13339.3b
196 schema:familyName Fiedor
197 schema:givenName Piotr
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152477672.41
199 rdf:type schema:Person
200 sg:person.0733571600.90 schema:affiliation grid-institutes:grid.13339.3b
201 schema:familyName Wroński
202 schema:givenName Jakub
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733571600.90
204 rdf:type schema:Person
205 sg:pub.10.1007/s00296-013-2772-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024479511
206 https://doi.org/10.1007/s00296-013-2772-6
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s10067-013-2387-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1008318128
209 https://doi.org/10.1007/s10067-013-2387-z
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s12016-017-8623-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090743106
212 https://doi.org/10.1007/s12016-017-8623-6
213 rdf:type schema:CreativeWork
214 sg:pub.10.1038/srep32768 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007149680
215 https://doi.org/10.1038/srep32768
216 rdf:type schema:CreativeWork
217 grid-institutes:grid.13339.3b schema:alternateName Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland
218 schema:name Department of General and Transplantation Surgery, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland
219 Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland
220 rdf:type schema:Organization
221 grid-institutes:grid.460480.e schema:alternateName Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland
222 schema:name Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637 Warsaw, Poland
223 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...